Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLIGOPELVIS2: IADT +/- Salvage IG-IMRT in Oligometastatic Prostate Cancer
NCT03630666Active, not recruiting
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Dec 2018
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Progression-Free Survival at 90 months. Started Dec 2018; status: active, not recruiting.
Beyond the preview
Go deeper on NCT03630666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630666.